A resurrection of 7-MEOTA: a comparison with tacrine

. 2013 Oct ; 10 (8) : 893-906.

Jazyk angličtina Země Spojené arabské emiráty Médium print

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid24093535

Alzheimer´s disease (AD) is a progressive neurodegenerative dementia which currently represents one of the biggest threats for the human kind. The cure is still unknown and various hypotheses (cholinergic, amyloidal, oxidative, vascular etc.) are investigated in order to understand the pathophysiology of the disease and on this basis find an effective treatment. Tacrine, the first approved drug for the AD disease treatment, has been reported to be a multitargeted drug, however it was withdrawn from the market particularly due to its hepatotoxicity. Its derivative 7-methoxytacrine (7- MEOTA) probably due to the different metabolization does not exert this side effect. The aim of our study was to compare these two cholinesterase inhibitors from various, mainly cholinergic, points of view relevant for a potential AD drug. We found that 7-MEOTA does not fall behind its more well-known parent compound - tacrine. Furthermore, we found, that 7-MEOTA exerts better properties in most of the tests related to a possible AD treatment. Only the pharmacokinetics and a higher acetylcholinesterase and butyrylcholinesterase inhibitory potency would slightly give advantages to tacrine over 7-MEOTA, but concerning its lower toxicity, better antioxidant properties, interaction with muscarinic and nicotinic receptors and "safer" metabolization provide strong evidence for reconsider 7-MEOTA and its derivatives as candidate molecules for the treatment of AD.

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

The Effect of Tacrine on Functional Response of the Lower Oesophageal Sphincter Assessed by Endoscopic Luminal Impedance Planimetry in Experimental Pigs

. 2024 Nov 25 ; 17 (12) : . [epub] 20241125

Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease

. 2023 May 23 ; 24 (11) : . [epub] 20230523

Privileged multi-target directed propargyl-tacrines combining cholinesterase and monoamine oxidase inhibition activities

. 2022 Dec ; 37 (1) : 2605-2620.

Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease

. 2021 Apr 22 ; 64 (8) : 4972-4990. [epub] 20210408

Effects of Novel Tacrine Derivatives on Mitochondrial Energy Metabolism and Monoamine Oxidase Activity-In Vitro Study

. 2021 Mar ; 58 (3) : 1102-1113. [epub] 20201022

Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and N-Methyl-d-Aspartate Receptor Antagonists

. 2020 Dec 22 ; 11 (1) : . [epub] 20201222

In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers

. 2019 Dec ; 34 (1) : 877-897.

Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors

. 2019 Aug 19 ; 9 (8) : . [epub] 20190819

Technological Solutions for Older People with Alzheimer's Disease: Review

. 2018 ; 15 (10) : 975-983.

Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment

. 2017 ; 15 (4) : 637-653.

In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity

. 2017 Oct ; 54 (8) : 5894-5904. [epub] 20160923

Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy

. 2017 Jul 28 ; 22 (8) : . [epub] 20170728

Novel Tacrine-Scutellarin Hybrids as Multipotent Anti-Alzheimer's Agents: Design, Synthesis and Biological Evaluation

. 2017 Jun 16 ; 22 (6) : . [epub] 20170616

A 7-methoxytacrine-4-pyridinealdoxime hybrid as a novel prophylactic agent with reactivation properties in organophosphate intoxication

. 2016 Jul 01 ; 5 (4) : 1012-1016. [epub] 20160525

7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment

. 2015 Dec 10 ; 20 (12) : 22084-101. [epub] 20151210

Alzheimer's disease and language impairments: social intervention and medical treatment

. 2015 ; 10 () : 1401-7. [epub] 20150827

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...